Buccal, polar and non-polar spray containing zolpidem
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-009/12
A61F-013/00
출원번호
US-0576457
(2009-10-09)
등록번호
US-8236285
(2012-08-07)
발명자
/ 주소
Dugger, III, Harry A.
Abd El-Shafy, Mohammed
출원인 / 주소
Novadel Pharma Inc.
대리인 / 주소
Dickstein Shapiro LLP
인용정보
피인용 횟수 :
3인용 특허 :
64
초록▼
Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem,
Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide zolpidem for rapid absorption through the oral mucosa, resulting in fast onset of effect. The buccal polar compositions of the invention comprise formulation I: aqueous polar solvent, zolpidem, and optional flavoring agent; formulation II: aqueous polar solvent, zolpidem, optionally flavoring agent, and propellant; formulation III: non-polar solvent, zolpidem, and optional flavoring agent; formulation IV: non-polar solvent, zolpidem, optional flavoring agent, and propellant; formulation V: a mixture of a polar solvent and a non-polar solvent, zolpidem, and optional flavoring agent; formulation VI: a mixture of a polar solvent and a non-polar solvent, zolpidem, optional flavoring agent, and propellant.
대표청구항▼
1. A method of administering zolpidem to a mammal to provide transmucosal absorption of a pharmacologically effective amount of zolpidem through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising: spraying the oral mucosa of the mammal with a buccal spray comp
1. A method of administering zolpidem to a mammal to provide transmucosal absorption of a pharmacologically effective amount of zolpidem through the oral mucosa of the mammal to the systemic circulatory system of the mammal, comprising: spraying the oral mucosa of the mammal with a buccal spray composition comprising in weight percent of the composition: zolpidem or a pharmaceutically acceptable salt thereof in an amount of between 0.1 and 25 percent by weight of the total composition; a polar solvent in an amount between 10 and 97 percent by weight of the total composition; and a propellant in an amount between 2 and 10 percent by weight of the total composition, wherein said propellant is a C3 to C8 hydrocarbon of linear or branched configuration; andwherein said spraying the oral mucosa results in transmucosal absorption of a pharmacologically effective amount of zolpidem through the oral mucosa to the systemic circulatory system of said mammal. 2. The method of claim 1, wherein the composition further comprises a taste mask and/or flavoring agent in an amount between 0.05 and 10 percent by weight of the total composition. 3. The method of claim 2, wherein the polar solvent is present in an amount between 20 and 97 percent by weight of the total composition, the zolpidem or a pharmaceutically acceptable salt thereof is present in an amount between 0.1 and 15 percent by weight of the total composition, the propellant is present in an amount between 2 and 5 percent by weight of the composition, and the taste mask and/or flavoring agent is present in an amount between 0.1 and 5 percent by weight of the total composition. 4. The method of claim 3, wherein the polar solvent is present in an amount between 25 and 97 percent by weight of the total composition, the zolpidem or a pharmaceutically acceptable salt thereof is present in an amount between 0.2 and 10 percent by weight of the total composition, the propellant is present in an amount between 2 and 4 percent by weight of the composition, and taste mask and/or flavoring agent is present in an amount between 0.1 and 2.5 percent by weight of the total composition. 5. The method of claim 1, wherein the polar solvent is selected from the group consisting of polyethyleneglycols having a molecular weight between 400 and 1000, C2 to C8 mono- and poly-alcohols, and C7 to C18 alcohols of linear or branched configuration. 6. The method of claim 1, wherein the polar solvent comprises polyethylene glycol. 7. The method of claim 1, wherein the polar solvent comprises ethanol. 8. The method of claim 2, wherein the flavoring agent is selected from the group consisting of synthetic or natural oil of peppermint, oil of spearmint, citrus oil, fruit flavors, sweeteners, and mixtures thereof. 9. The method of claim 1, wherein the propellant is selected from the group consisting of propane, N-butane, iso-butane, N-pentane, iso-pentane, neo-pentane, and mixtures thereof. 10. The method of claim 1, wherein the amount of the spray is predetermined.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (64)
Nagy Margit (Budapest HUX) Kenderfi Jzsef (Budapest HUX) Grgnyi Frigyes (Budapest HUX) Csrgo Margit (Budapest HUX) Fedina Lidia (Budapest HUX) Mosonyi Antal (Krmend HUX) Vajas Sndor (Krmend HUX) Mndi, Aerosol composition comprising nitroglycerin as active ingredient.
Duan Daniel C. ; Stefely James S. ; Schultz David W. ; Leach Chester L., Aerosol formulation containing an ester-, amide-, or mercaptoester-derived dispersing aid.
Viegas Tacey X. (Ann Arbor MI) Reeve Lorraine E. (Ann Arbor MI) Henry Raymond L. (Grosse Pointe Woods MI), Body cavity drug delivery with thermo-irreversible polyoxyalkylene and ionic polysaccharide gels.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Kanios David P. ; Gentile Joseph A. ; Mantelle Juan A. ; Sablotsky Steven, Compositions and methods for topical administration of pharmaceutically active agents.
Ko Kenneth D. ; Anderton David O. ; Eldumiati Ismail I. ; Gronemeyer Steven A. ; Harmer Don L. ; Henderson P. Michael ; Peshkin Joel D. ; Rahamim Raphael ; Stubbe Frederic M. ; Walley John S. ; Walle, Constant envelope modulation for splitterless DSL transmission.
Dvorsky Stephan (Binningen CHX) Radivojevich Franz (Zofingen CHX) Joss Hans (Murgenthal CHX), Coronary therapeutic agent in the form of soft gelatin capsules.
Keller Brian C. ; Fisher Daniel L. ; Kiss Steven, Delivery of biologically active material in a liposomal formulation for administration into the mouth.
Reed Barry Leonard,AUX ; Morgan Timothy Matthias,AUX ; Finnin Barrie Charles,AUX, Dermal penetration enhancers and drug delivery systems involving same.
Dixit Suresh C. (Neshamic Station NJ) Goldman David (Hillsdale NJ) Hu John J. (Huntington CT) Sethachutkul Krish (Scarsdale NY), Dispersing agents for use with hydrofluoroalkane propellants.
Jinks Philip A. (Mountsorrel GB3) Bell Alexander (Chilwell GB3) Fischer Franz X. (Riehen CHX), Drug-containing chlorofluorocarbon aerosol propellent formulations.
Baker Richard W. (Palo Alto CA) Santus Giancarlo (Milan ITX) Vintilla-Friedman Susan (Cupertino CA), Method and therapeutic system for smoking cessation.
Bechgaard Erik (Hellerup DKX) Gizurarson Sveinbjrn (Keflavik ISX) Hjortkjaer Rolf K. (Humlebaer DKX), Method of administering a biologically active substance.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
Patel Dinesh C. (Murray UT) Chang Yunik (Lakewood NJ), Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols.
Burghart Walter (A-1030 Vienna ; Salmgasse 4 Vienna ATX) Burghart Kurt (D-2217 Rosdorf ; Saegeberg 8 Rosdorf DEX), Pharmaceutical preparation and methods for its production.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.